Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations
Authors:
- Nathaniel KatzNKNathaniel Katz
- Robert H. DworkinRDRobert H. Dworkin
- Richard NorthRNRichard North
- Simon ThomsonSTSimon Thomson
- Sam EldabeSESam Eldabe
- Salim M. HayekSHSalim M. Hayek
- Brian H. KopellBKBrian H. Kopell
- John MarkmanJMJohn Markman
- Ali RezaiARAli Rezai
- Rod S. TaylorRTRod S. Taylor
- Dennis C. TurkDTDennis C. Turk
- Eric BuchserEBEric Buchser
Open Access
- 18 January 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (7) , 1935-1956
Abstract
Spinal cord stimulation (SCS) is an interventional nonpharmacologic treatment used for chronic pain and other indications. Methods for evaluating the safety and efficacy of SCS have evolved from uncontrolled and retrospective studies to prospective randomized controlled trials (RCTs). Although randomization overcomes certain types of bias, additional challenges to the validity of RCTs of SCS include blinding, choice of control groups, nonspecific effects of treatment variables (eg, paresthesia, device programming and recharging, psychological support, and rehabilitative techniques), and safety considerations. To address these challenges, 3 professional societies (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, Institute of Neuromodulation, and International Neuromodulation Society) convened a meeting to develop consensus recommendations on the design, conduct, analysis, and interpretation of RCTs of SCS for chronic pain. This article summarizes the results of this meeting. Highlights of our recommendations include disclosing all funding source and potential conflicts; incorporating mechanistic objectives when possible; avoiding noninferiority designs without internal demonstration of assay sensitivity; achieving and documenting double-blinding whenever possible; documenting investigator and site experience; keeping all information provided to patients balanced with respect to expectation of benefit; disclosing all information provided to patients, including verbal scripts; using placebo/sham controls when possible; capturing a complete set of outcome assessments; accounting for ancillary pharmacologic and nonpharmacologic treatments in a clear manner; providing a complete description of intended and actual programming interactions; making a prospective ascertainment of SCS-specific safety outcomes; training patients and researchers on appropriate expectations, outcome assessments, and other key aspects of study performance; and providing transparent and complete reporting of results according to applicable reporting guidelines.Keywords
This publication has 140 references indexed in Scilit:
- Concealment and fabrication by experienced research subjectsClinical Trials, 2013
- Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendationsPain, 2013
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2012
- CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trialsInternational Journal of Surgery, 2012
- Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT databaseOsteoarthritis and Cartilage, 2011
- Patient and Practitioner Influences on the Placebo Effect in Irritable Bowel SyndromePsychosomatic Medicine, 2009
- Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research CentersJournal of Allergy and Clinical Immunology, 2009
- Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More UnderstandableJournal of Pain and Symptom Management, 2006
- Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA, 1995
- Temporary Abolition of Pain in ManScience, 1967